• SPX
  • $5,970.86
  • 0.37 %
  • $22.15
  • DJI
  • $44,232.17
  • 0.82 %
  • $361.81
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,017.31
  • 0.24 %
  • $44.89
Immutep Limited (IMMP) Stock Price, News & Analysis

Immutep Limited (IMMP) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.93

$0.09

(4.89%)

Day's range
$1.87
Day's range
$1.96
50-day range
$1.77
Day's range
$2.41
  • Country: AU
  • ISIN: US45257L1089
52 wk range
$1.66
Day's range
$3.34


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.20
  • Piotroski Score 3.00
  • Grade Outperform
  • Symbol (IMMP)
  • Company Immutep Limited
  • Price $1.93
  • Changes Percentage (4.89%)
  • Change $0.09
  • Day Low $1.87
  • Day High $1.96
  • Year High $3.34

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $8.50
  • High Stock Price Target $10.00
  • Low Stock Price Target $7.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.27
  • Trailing P/E Ratio -9.89
  • Forward P/E Ratio -9.89
  • P/E Growth -9.89
  • Net Income $-42,716,625

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Immutep Limited Frequently Asked Questions

  • What were the earnings of IMMP in the last quarter?

    In the last quarter Immutep Limited earnings were on Tuesday, February, 22nd. The Immutep Limited maker reported -$0.01 EPS for the quarter, beating analysts' consensus estimates of -$0.23 by $0.22.

  • What is the Immutep Limited stock price today?

    Today's price of Immutep Limited is $1.93 — it has increased by +4.89% in the past 24 hours. Watch Immutep Limited stock price performance more closely on the chart.

  • Does Immutep Limited release reports?

    Yes, you can track Immutep Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Immutep Limited stock forecast?

    Watch the Immutep Limited chart and read a more detailed Immutep Limited stock forecast to see what analysts suggest you do with its shares.

  • What is Immutep Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Immutep Limited stock ticker.

  • How to buy Immutep Limited stocks?

    Like other stocks, IMMP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Immutep Limited's EBITDA?

    Immutep Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Immutep Limited’s financial statements.

  • What is the Immutep Limited's net income ratio for the financial year 2024?

    The net income ratio for the financial year 2024 is -11.1186862567, which equates to approximately -1,111.87%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Immutep Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Immutep Limited's financials relevant news, and technical analysis. Immutep Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Immutep Limited stock currently indicates a “sell” signal. For more insights, review Immutep Limited’s technical analysis.

  • A revenue figure for Immutep Limited for its last quarter?

    Immutep Limited published it's last quarterly revenues at $1.73 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.